This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
|Articles|April 22, 2014
PolyPeptide Group
PolyPeptide Group is a leading provider of custom/generic peptides for research and pharmaceutical applications with 6 facilities worldwide. Our focus is on proprietary and generic GMP-grade peptides for the pharmaceutical and biotechnological market. With more than 50 years of experience, we are committed to the highest quality of peptide manufacturing for every stage of product development.
Advertisement
PolyPeptide Group
PolyPeptide Group is a leading provider of custom/generic peptides for research and pharmaceutical applications with 6 facilities worldwide. Our focus is on proprietary and generic GMP-grade peptides for the pharmaceutical and biotechnological market. With more than 50 years of experience, we are committed to the highest quality of peptide manufacturing for every stage of product development.
Company name: PolyPeptide Group
Website:
E-mail:
Advertisement
Related to this article
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Advertisement
Advertisement